Gene expression profiles as biomarkers for the prediction of chemotherapy drug response in human tumour cells.
Genome profiling approaches such as cDNA microarray analysis and quantitative reverse transcription polymerase chain reaction are playing ever-increasing roles in the classification of human cancers and in the discovery of biomarkers for the prediction of prognosis in cancer patients. Increasing research efforts are also being directed at identifying set of genes whose expression can be correlated with response to specific drugs or drug combinations. Such genes hold the prospect of tailoring chemotherapy regimens to the individual patient, based on tumour or host gene expression profiles. This review outlines recent advances and challenges in using genome profiling for the identification of tumour or host genes whose expression correlates with response to chemotherapy drugs both in vitro and in clinical studies. Genetic predictors of response to a variety of anticancer agents are discussed, including the anthracyclines, taxanes, topoisomerase I and II inhibitors, nucleoside analogs, alkylating agents, and vinca alkaloids.
Parissenti
Amadeo M
AM
Tumour Biology Research Program, Sudbury Regional Hospital, Department of Biology, Laurentian University, Sudbury, Ottawa, Ontario, Canada. aparissenti@hrsrh.on.ca
Hembruff
Stacey L
SL
Villeneuve
David J
DJ
Veitch
Zachary
Z
Guo
Baoqing
B
Eng
Jamei
J
D000818:Animals; D018943:Anthracyclines / Q000494:pharmacology; D000970:Antineoplastic Agents / Q000494:pharmacology*; D018906:Antineoplastic Agents, Alkylating / Q000494:pharmacology; D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology; D015415:Biomarkers / Q000032:analysis*; D002166:Camptothecin / Q000031:analogs & derivatives / Q000494:pharmacology; D045744:Cell Line, Tumor; D020869:Gene Expression Profiling; D006801:Humans; D009705:Nucleosides / Q000494:pharmacology; D011237:Predictive Value of Tests; D043823:Taxoids / Q000494:pharmacology; D059004:Topoisomerase I Inhibitors; D059005:Topoisomerase II Inhibitors; D014748:Vinca Alkaloids / Q000494:pharmacology
D018943:Anthracyclines; D000970:Antineoplastic Agents; D018906:Antineoplastic Agents, Alkylating; D000972:Antineoplastic Agents, Phytogenic; D015415:Biomarkers; D009705:Nucleosides; D043823:Taxoids; D059004:Topoisomerase I Inhibitors; D059005:Topoisomerase II Inhibitors; D014748:Vinca Alkaloids; D002166:Camptothecin